Despite a flat quarter and a SEK 20 million inventory write-down, EQL Pharma AB (FRA:7JK) reaffirms its full-year guidance, citing improved stock availability and a robust pipeline.

EQL Pharma (OM:EQL) is forecasting robust growth, with earnings expected to climb 59.6% per year and revenue set to increase 30.4% per year, both well ahead of broader Swedish market expectations. However, net profit margins fell to 7.4% versus 9.9% last year, and the current Price-to-Earnings Ratio sits at 54.3x, which is higher than the European Healthcare industry average of 17.6x but still below the peer average of 60x. Over the past five years, the company’s earnings have grown by 19.1%...

Despite a challenging quarter with supply chain disruptions, EQL Pharma AB (OSTO:EQL) focuses on strategic launches and market expansions to drive future growth.